MedDataX Logo

A Phase 2 Study Of PF-00232798 In HIV Positive Patients

NCT ID: NCT00495677

Last Updated: 2013-10-30

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

43 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-06-30

Study Completion Date

2008-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To assess the viral load response, safety, tolerability and pharmacokinetics of multiple oral doses of PF 00232798 in HIV-positive patient volunteers.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Treatment Experienced Treatment Naive

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PF-00232798 40 mg

Group Type ACTIVE_COMPARATOR

PF-00232798

Intervention Type DRUG

Solution, 40 mg. once daily, 10 days

PF-00232798 300 mg

Group Type ACTIVE_COMPARATOR

PF-00232798

Intervention Type DRUG

Solution, 300 mg. once daily, 10 days

PF-00232798 400 mg

Group Type ACTIVE_COMPARATOR

PF-00232798

Intervention Type DRUG

Solution, 400 mg. once daily, 10 days

PF-00232798 5 mg

Group Type ACTIVE_COMPARATOR

PF-00232798

Intervention Type DRUG

Solution, 5 mg. once daily, 10 days

PF-00232798 20 mg

Group Type ACTIVE_COMPARATOR

PF-00232798

Intervention Type DRUG

Solution, 20 mg. once daily, 10 days

PF-00232798 150 mg

Group Type ACTIVE_COMPARATOR

PF-00232798

Intervention Type DRUG

Solution, 150 mg. once daily, 10 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PF-00232798

Solution, 20 mg. once daily, 10 days

Intervention Type DRUG

PF-00232798

Solution, 150 mg. once daily, 10 days

Intervention Type DRUG

PF-00232798

Solution, 5 mg. once daily, 10 days

Intervention Type DRUG

PF-00232798

Solution, 40 mg. once daily, 10 days

Intervention Type DRUG

PF-00232798

Solution, 300 mg. once daily, 10 days

Intervention Type DRUG

PF-00232798

Solution, 400 mg. once daily, 10 days

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Asymptomatic HIV-1 infected male patients between the ages of 18 and 55 years inclusive.
* Patients with CCR5 tropic virus as determined by the Monogram PhenoSense Entry assay.

Exclusion Criteria

* Patients who have received any experimental drug within the past four months (prior to the first dosing day of the study) or who have previously received another CCR5 antagonist.
* Patients with evidence of decompensated liver disease.
Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Pfizer Investigational Site

Cologne, , Germany

Site Status

Pfizer Investigational Site

Frankfurt am Main, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

Related Links

Access external resources that provide additional context or updates about the study.

https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A7691009&StudyName=A%20Phase%202%20Study%20Of%20PF-00232798%20In%20HIV%20Positive%20Patients.

To obtain contact information for a study center near you, click here.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

A7691009

Identifier Type: -

Identifier Source: org_study_id